ClinicalTrials.Veeva

Menu

Emergency Stroke Unit for Acute Cerebrovascular Events ( ESU-ACE-C )

Capital Medical University logo

Capital Medical University

Status and phase

Enrolling
Phase 3

Conditions

Ischemic Stroke, Acute

Treatments

Combination Product: Emergency Stroke Unit based on 0.23-T MRI
Combination Product: Standard stroke unit adherent to guidelines

Study type

Interventional

Funder types

Other

Identifiers

NCT06522269
KY2024-131-02-C

Details and patient eligibility

About

To compare the prognosis of patients with hyperacute ischemic stroke (within 4.5 hours after the onset of symptoms) managed in a standard stroke unit adherent to guidelines versus managed in Emergency Stroke Unit (a new stroke unit based on low-field magnetic resonance imaging).

Full description

The first MRI machines in the 1970s and 1980s were low-field due to technological limitations. As technology advanced, the focus shifted to higher field strengths to achieve better image resolution and faster scan times. Recently, there has been renewed interest in low-field MRI due to advancements in hardware and software, making them more viable for specific clinical applications, including acute stroke. Prompt and accurate imaging is crucial for diagnosing ischemic stroke and determining the appropriate treatment (e.g., thrombolysis or thrombectomy). Research has demonstrated that low-field MRI can effectively detect acute ischemic changes and distinguish between ischemic and hemorrhagic stroke. By providing accessible, cost-effective, and safe imaging, it can facilitate timely and accurate treatment, particularly in settings where high-field MRI is not readily available. This prospective, multicenter, week-wise randomized controlled trial will compare the prognosis of patients with hyperacute ischemic stroke (within 4.5 hours after the onset of symptoms) managed in a standard stroke unit adherent to guidelines versus managed in Emergency Stroke Unit (a new stroke unit based on low-field magnetic resonance imaging).

Enrollment

1,622 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age ≥ 18 years;
  2. Can be treated within 4.5 hours of symptoms onset*(*Symptom onset is defined by the "last seen normal" principle);
  3. Presenting with ischemic stroke symptoms;
  4. Pre-stroke mRS score 0-1;
  5. Baseline NIHSS score ≥ 5;
  6. Eligible for rt-PA/TNK thrombolysis;
  7. Informed consent signed.

Exclusion criteria

  1. Baseline NIHSS score < 5;
  2. Unable to undergo MRI because of claustrophobia;
  3. Patients with cardiac pacemaker/brain pacemaker/insulin pump implantation;
  4. Definite contraindication for rt-PA/TNK thrombolysis;
  5. Patients with postictal hemiparesis (Todd's paralysis) or those with concomitant neurological/psychiatric conditions who are unable or unwilling to cooperate;
  6. Pregnant women, nursing mothers, or reluctance to use effective contraceptive measures during the period of trial;
  7. Participation in other interventional randomized clinical trials within 3 months before enrollment;
  8. Patients deemed unsuitable for participation in this trial by the investigator or those for whom participation in this trial may result in greater risks.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

1,622 participants in 2 patient groups, including a placebo group

Emergency Stroke Unit based on 0.23-T MRI
Experimental group
Description:
The participants with hyperacute ischemic stroke (symptoms onset ≤4.5 h) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
Treatment:
Combination Product: Emergency Stroke Unit based on 0.23-T MRI
Standard stroke unit adherent to guidelines
Placebo Comparator group
Description:
The participants with hyperacute ischemic stroke (symptoms onset ≤4.5 h) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
Treatment:
Combination Product: Standard stroke unit adherent to guidelines

Trial contacts and locations

1

Loading...

Central trial contact

Yongjun Wang; Jing jing

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems